Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 1.59
1.27 %
$ 36.4 M
Market Cap
-1.96
P/E
1. INTRINSIC VALUE
Balance Sheet
Femasys Inc.
| Current Assets | 23.2 M |
| Cash & Short-Term Investments | 21.7 M |
| Receivables | 98.9 K |
| Other Current Assets | 1.36 M |
| Non-Current Assets | 4.58 M |
| Long-Term Investments | 0 |
| PP&E | 3.49 M |
| Other Non-Current Assets | 1.09 M |
| Current Liabilities | 3.05 M |
| Accounts Payable | 1.14 M |
| Short-Term Debt | 407 K |
| Other Current Liabilities | 1.51 M |
| Non-Current Liabilities | 6.35 M |
| Long-Term Debt | 6.29 M |
| Other Non-Current Liabilities | 54.9 K |
EFFICIENCY
Earnings Waterfall
Femasys Inc.
| Revenue | 1.07 M |
| Cost Of Revenue | 380 K |
| Gross Profit | 692 K |
| Operating Expenses | 15.2 M |
| Operating Income | -14.5 M |
| Other Expenses | -261 K |
| Net Income | -14.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Femasys Inc.
| Net Income | -14.2 M |
| Depreciation & Amortization | 908 K |
| Capital Expenditures | -144 K |
| Stock-Based Compensation | 676 K |
| Change in Working Capital | 1.22 M |
| Others | 1.01 M |
| Free Cash Flow | -11.4 M |
Wall Street Analysts Price Targets
Femasys Inc.
FEMY has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
FEMY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Femasys Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 years ago
Jun 22, 2021
|
Bought
1.3 M USD
|
Uzialko Edward R
Director
|
+ 100000
|
13 USD |
|
3 years ago
Jun 22, 2021
|
Bought
91 K USD
|
Larsen Charles
Director
|
+ 7000
|
13 USD |
|
3 years ago
Jun 22, 2021
|
Bought
520 K USD
|
Adams John Q JR
Director
|
+ 40000
|
13 USD |
|
3 years ago
Jun 23, 2021
|
Bought
9.95 K USD
|
Dyett John
director, 10 percent owner:
|
+ 1000
|
9.95 USD |
|
3 years ago
Jun 22, 2021
|
Bought
520 K USD
|
Dyett John
director, 10 percent owner:
|
+ 40000
|
13 USD |
|
3 years ago
Jun 18, 2021
|
Bought
129 K USD
|
Dyett John
director, 10 percent owner:
|
+ 10000
|
12.88 USD |
|
3 years ago
Jun 18, 2021
|
Bought
33 K USD
|
Dyett John
director, 10 percent owner:
|
+ 2500
|
13.18 USD |
7. News
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products Regulatory Agency (MHRA) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection. “This is another key milestone as we expand our reach to the UK following successful approval across Europe for our innovative infertility and cancer detection products.
globenewswire.com
- 2 weeks ago
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
globenewswire.com
- 1 month ago
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys' therapeutic option for women seeking infertility solution
globenewswire.com
- 1 month ago
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
globenewswire.com
- 3 months ago
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
zacks.com
- 3 months ago
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
globenewswire.com
- 3 months ago
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control
globenewswire.com
- 4 months ago
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
globenewswire.com
- 4 months ago
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
globenewswire.com
- 5 months ago
Femasys Announces Infertility Clinic Customers from Coast to Coast
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
globenewswire.com
- 5 months ago
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products
globenewswire.com
- 5 months ago
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
zacks.com
- 5 months ago
8. Profile
Summary
Femasys Inc. FEMY
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 36.4 M
Dividend Yield
0.00%
Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Contact
3950 Johns Creek Court, Suwanee, GA, 30024
https://www.femasys.com
IPO
Date
June 18, 2021
Employees
32
Officers
Ms. Christine Thomas
Senior Vice President of Regulatory & Clinical Affairs
Mr. Richard Spector
Chief Commercial Officer
Mr. Dov Elefant
Chief Financial Officer
Ms. Naomi Phaneuf
Vice President of Marketing
Ms. Mary An Merchant J.D., Ph.D.
Vice President of Counsel & Intellectual Property
Dr. Jeffrey Marcus M.D., M.S.
Chief Medical Advisor
Dr. James H. Liu M.D.
Chief Medical Officer
Mr. Daniel Scott Currie
Chief Operating Officer, Senior Vice President & Secretary
Mr. Benjamin Dings
Vice President of Sales
Ms. Kathy Lee-Sepsick M.B.A.
Founder, President, Chief Executive Officer & Director